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Anabasum is a synthetic analog ofD8-tetrahydrocannabinol (THC)-11-oic acid that in preclinical models of experimental
inflammation exerts potent anti-inflammatory actions with minimal central nervous system (CNS) cannabimimetic activity.
Here we used a novel model of acute inflammation driven by i.d. UV-killed E. coli in healthy humans and found that anaba-
sum (5mg) exerted a potent anti-inflammatory effect equivalent to that of prednisolone in terms of inhibiting neutrophil
infiltration, the hallmark of acute inflammation. These effects arose from the inhibition of the neutrophil chemoattractant
LTB4, while the inhibition of antiphagocytic prostanoids (PGE2, TxB2, and PGF2a) resulted in enhanced clearance of inflam-
matory stimulus from the injected site. Anabasum at the higher dose of 20mg possessed the additional properties of trig-
gering the biosynthesis of specialized pro-resolving lipid mediators including LXA4, LXB4, RvD1, and RvD3. Collectively, we
demonstrate for the first time a striking anti-inflammatory and pro-resolution effects of a synthetic analog of THC in healthy
humans.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
While nonsteroidal anti-inﬂammatory drugs, steroids, and bio-
logics dampen the cardinal signs of inﬂammation, they can derail
pro-resolution pathways, thereby propagating the underlying dis-
ease. Moreover, they exert organ-based sides effects, with some
compromising antimicrobial host defense. Thus, more tolerable
pharmaceutics with novel mechanisms of actions and possessing
equal or greater efﬁcacy to the current regimes is required.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Is anabasum, a novel cannabinoid receptor 2 agonist, anti-
inﬂammatory and pro-resolution in a novel proof-of-concept
model of UV-killed E. coli-triggered dermal inﬂammation in
humans?
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Anabasum is strikingly immune-suppressive in humans. It
inhibited neutrophil inﬁltration, caused enhanced clearance of
the injected antigen, and also triggered the biosynthesis of spe-
cial pro-resolution lipid mediators leading to pronounced abate-
ment of the inﬂammatory response.
HOW THIS MIGHT CHANGE CLINICAL PHARMA-
COLOGY OR TRANSLATIONAL SCIENCE
 Despite being potently immune-suppressive, anabasum para-
doxically triggered bacterial clearance while also activating
pro-resolution pathways, a ﬁrst in humans. This, alongside its
favorable safety proﬁle, suggests that anabasum is a promising
new drug for the treatment of inﬂammation-driven diseases.
The current therapeutic strategy for treating chronic inﬂamma-
tory diseases is based largely on inhibiting the factors that drive
acute inﬂammation and includes nonsteroidal anti-inﬂammatory
drugs,1 steroids,2 and anti-TNFa therapies.3 Although these
medicines ameliorate some disease symptoms, they do not bring
about a “cure” and are ineffective in a signiﬁcant subset of
patients. Furthermore, they can hamper endogenous homeostatic
systems resulting in serious adverse effects including predisposing
to infection, gastrointestinal toxicity, as well as cardiac and meta-
bolic imbalances. Thus, there is a signiﬁcant need to identify
more effective and safer therapeutics to treat chronic inﬂamma-
tory diseases. One emerging approach is to harness the body’s
own inﬂammatory resolution process for therapeutic gain.4
Consequently, attention has turned to the other end of the
inﬂammatory spectrum, resolution, to understand the endoge-
nous processes involved in switching off inﬂammation. Our
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approach was to identify novel internal counter-regulatory sys-
tems that naturally terminate inﬂammation in order to provide
new pharmacological targets that can be activated to treat exces-
sive inﬂammation through a pro-resolution pathway.5 Over the
past decade, inﬂammatory resolution has been extensively studied
and conclusively demonstrated to be an active process with quan-
tiﬁable indices and speciﬁc physiological requirements.6 For
instance, it has become clear that for effective resolution to occur
the inﬂammatory stimulus must ﬁrst be eliminated.7,8 Thereafter,
prior to resolution being initiated, proinﬂammatory cytokines/
chemokines are catabolized,9,10 while inﬁltrated effector neutro-
phils die through apoptosis,11 which allows for their nonphlogis-
tic efferocytosis by cells of the monocyte/macrophage lineage.12
Having recently characterized a human model of resolution of
inﬂammation triggered by intradermal injection of UV-killed E.
coli (UVkEc) into the forearms of healthy volunteers,13 we
sought to test a drug, from the published literature, that possessed
anti-inﬂammatory as well as potential pro-resolution properties.
Anabasum is a synthetic analog of D8-tetrahydrocannabinol
(THC)-11-oic acid, the terminal metabolite of D8-THC. Unlike
D9-THC, the psychoactive principle of cannabis, it shows potent
anti-inﬂammatory action with minimal central nervous system
(CNS) cannabimimetic activity as a result of its CB2 receptor
selectivity and limited penetration of the blood–brain barrier.14
The CB2 receptor is preferentially expressed on activated
immune cells where it is believed to mediate the immune modu-
latory properties of cannabis. For instance, the anti-inﬂammatory
effects of anabasum have been demonstrated in a number of ani-
mal models including an arachidonic acid-induced rodent paw
model, where it blocked swelling,15 and in a rat adjuvant-induced
arthritis, where it suppressed joint swelling and prevented the
development of cartilage and bone erosion that is typical of this
aggressive model of chronic inﬂammation.16 Evidence of pro-
resolution properties of anabasum have also been demonstrated
using synovial ﬁbroblasts, where it triggers the biosynthesis of 15-
deoxy-D12,14-PGJ2,
17 originally shown by us to be expressed dur-
ing the resolution phase of acute rat pleuritis18 and in a mouse
peritonitis model, where it reduced the inﬁltration of neutrophils
and stimulated the biosynthesis of the specialized pro-resolution
lipid mediator (SPM) lipoxin A4.
19 In addition, anabasum has
been shown to trigger the biosynthesis of lipoxin A4 from lipo-
polysaccharide (LPS)-stimulated human whole blood and syno-
vial cells.19 Collectively, in addition to being anti-inﬂammatory,
there is emerging evidence that anabasum may also activate pro-
resolution pathways.
Anabasum is currently being evaluated in double-blinded phase
II clinical trials for the treatment of cystic ﬁbrosis, diffuse cutane-
ous systemic sclerosis (”systemic sclerosis”), dermatomyositis, and
systemic lupus erythematosus, four indications in which inﬂam-
mation contributes to disease progression (clinicaltrial.gov identi-
ﬁer: NCT02465450, NCT02465437, NCT02466243). We
investigated whether anabasum ameliorates inﬂammation in a
human model of acute inﬂammation and sought to determine
the mechanism by which it works. Prednisolone was used as a
positive control because of its clinical potency in treating diseases
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efferocytosis of apoptotic bodies, a key determinant of inﬂamma-
tory resolution.20,21 Anabasum exhibited potent anti-inﬂamma-
tory activity, being equivalent to prednisolone as deﬁned by the
inhibition of neutrophil numbers at the site of bacterial injection.
Anabasum also triggered the biosynthesis of SPMs and brought
about the clearance of the injected bacteria as measured by endo-
toxin levels, thereby paving the way for effective resolution to
occur. This is the ﬁrst study of its kind to demonstrate in humans
that anabasum is a unique anti-inﬂammatory drug that acts on
both the onset and resolution cascades of inﬂammation.
RESULTS
Volunteer recruitment and compliance
Twenty-eight volunteers were screened, and ﬁve volunteers were
excluded. The reasons for exclusion were following: out of
reference range blood counts (n5 2), high body mass index
(BMI) (n5 1), needle phobia (n5 1), and loss to follow-up
(n5 1). The remaining 23 volunteers were randomized into the
four study groups. In the placebo group, two volunteers were
excluded. The ﬁrst volunteer was excluded on day 3 because his
serum creatinine levels went above the reference range. Follow-
up investigation by a study clinician revealed that it was due to
dehydration. The other volunteer was excluded during analysis,
having missed the scheduled 4-h blister timepoint. In the 5mg
b.i.d. anabasum group, one volunteer was excluded on day 3 as
his platelet count was found to be below the reference range.
Follow-up investigation by a study clinician indicated the low
platelet count was not related to the drug. In total, data were
collected from 20 volunteers, and each group had ﬁve volunteers
(Figure 2).
Figure 2 Consort diagram of the open label, randomized, parallel group, placebo-controlled clinical study to test effect of 5 mg anabasum, 20 mg anaba-
sum, and prednisolone on anti-inflammatory and pro-resolution biomarkers in UVkEc triggered self-resolving dermal inflammation model.
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Anabasum is anti-inflammatory in a human model of acute
inflammation
Injecting UVkEc into the dermis of healthy male volunteers eli-
cited a robust local inﬁltration of neutrophils followed by phago-
cytosing monocyte-derived macrophage populations with the
response resolving within 48–72 h. Anabasum inhibited neutro-
phil numbers at the peak of inﬂammatory onset (4 h) by about
85% compared to the placebo control; this profound suppressive
effect was seen with both 5mg b.i.d. (P5 0.005) and 20mg b.i.d.
(P5 0.008) and was similar to the inhibition brought about by
prednisolone (P5 0.01) (Figure 3a). In contrast, neither doses
of anabasum affected the numbers of macrophages (Figure 3b),
which increased from 4–10 h coincident with their established
role in clearing dead/dying neutrophils and in affecting resolu-
tion. Interestingly, prednisolone exerted a trend towards reduc-
tion in macrophage numbers compared to placebo at 4 h that was
signiﬁcant at 10 h (P  0.05, Figure 3b).
We have noted that as inﬂammation progresses towards resolu-
tion in this model, macrophages acquire increased expression of
CD163 as a consequence of efferocytosing apoptotic neutro-
phils.13 Anabasum did not elevate CD163 level on inﬁltrating
macrophages (Figure 3c), while prednisolone exerted a trend
towards an increase consistent with its role in enhancing efferocy-
tosis.20,21 These data provide some insight into the mechanisms
of action of anabasum in this model, where inhibition of neutro-
phil inﬁltration is more obvious than enhancing neutrophil
clearance/efferocytosis.
Unlike their inhibitory effect on neutrophil inﬁltration at the
local site of UVkEc-triggered acute inﬂammation, anabasum and
prednisolone caused no signiﬁcant changes in peripheral blood
neutrophils or blood monocytes at 4 h or 10 h and was without
effect on peripheral blood C-reactive protein (CRP) levels (Sup-
plemental Figure S1).
Effects of anabasum on inflammatory cytokines
Despite the striking effect of anabasum on neutrophil trafﬁcking,
it had only a modest effect on concentrations of typical cytokines/
chemokines known to drive or inhibit acute inﬂammation includ-
ing tumor necrosis factor alpha (TNFa) and interleukin (IL)-1b
(Figure 4a–h). Most notable was a dose-dependent, although sta-
tistically insigniﬁcant, reduction in concentrations of IL-8 at the
local site of inﬂammation. Indeed, prednisolone was equally unre-
markable in this regard, exerting a signiﬁcant effect on interferon
gamma only at 4 h, P  0.05 (Figure 4c).
Effects of anabasum on lipid mediator biosynthesis
Targeted lipid mediator metabololipidomics was carried out on
the inﬂammatory exudate obtained from the site of UVkEc-
induced inﬂammation at both 4 h and 10 h. The 4-h timepoint
represents the switch from onset to resolution as deﬁned by the
beginning of neutrophil clearance and cytokine/chemokine
catabolism—established determinants of resolution. Indeed, in
support of this we found a temporal switch in lipid mediator
families from prostanoids to SPMs. At both 4 h and 10 h,
anabasum-treated volunteers gave a distinct lipid mediator proﬁle
characterized by a decrease in levels of proinﬂammatory
prostaglandin PGE2, thromboxane TXB2, PGF2a and leukotri-
ene LTB4 and a concomitant increase in levels of pro-resolving
mediators including LXA4, RvD1, and RvD3 (Figure S2).
The main effects of anabasum on SPM concentrations were at
the highest dose of 20mg b.i.d., where it elevated RvD1 and
Figure 3 Anabasum inhibits neutrophil migration to the site of UVkEc trig-
gered dermal inflammation. Healthy male volunteers were randomized to
receive by oral route either placebo, 5 mg anabasum, 20 mg anabasum,
twice daily, or 15mg prednisolone once daily for 4 days. On the fourth day,
acute inflammation was triggered by intradermal injection of 1.53 107 UV-
killed E. coli (UVkEc) suspended in 100 lL of saline in both forearms. Inflam-
matory exudate at the injection site was acquired into a suction blister raised
after 4 h (onset phase) on one forearm and after 10h (resolution phase) on
the contralateral forearm. Cells in the exudate were phenoytped by multicolor
flow cytometry. Neutrophil count/mL (a), monocyte/macrophage count/mL
(b), and surface expression of CD163 on monocytes/macrophages at 4 h
and 10 h is shown here (c). Data expressed as individual values with
mean6SD. n55/group. *P < 0.05, **< 0.01.
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RvD3 at 4 h; an equivalent increase was also seen at 10 h. Pred-
nisolone increased RvD1 at both timepoints but was without
effect on RvD3. Anabasum caused a trend towards an increase in
LXA4 and LXB4 at 20mg b.i.d. only, being signiﬁcant at 10 h for
LXA4 (Figure 5a–e).
In contrast, anabasum brought about a dose-dependent inhibi-
tion in concentrations of PGE2, TXB2, PGF2a, and LTB4 within
the elicited blister ﬂuid at both 4 h and 10 h, reaching statistical
signiﬁcance at the highest does of 20mg b.i.d.. These suppressive
effects on cyclooxygenase and lipoxygenase activity were seen also
with prednisolone (Figure 5f–j).
A post-hoc analysis of these data revealed that when anabasum
reduced LTB4 levels at 20mg b.i.d. there was a corresponding sig-
niﬁcant reduction in neutrophils (Figure S3).
Figure 4 Effects of anabasum and prednisolone on cytokine and chemokine biosynthesis. Healthy male volunteers were randomized to receive by oral
route either placebo, 5 mg anabasum, 20 mg anabasum, twice daily, or 15 mg prednisolone once daily for 4 days. On the fourth day, acute inflammation
was triggered by intradermal injection of 1.5 3 107 UV-killed E. coli (UVkEc) suspended in 100 lL of saline in both forearms. Inflammatory exudate at the
injection site was acquired into a suction blister raised after 4 h (onset phase) on one forearm and after 10 h (resolution phase) on the contralateral fore-
arm. Cytokines and chemokines in the inflammatory exudate were measured by multiplex enzyme-linked immunosorbent assay (ELISA). The concentra-
tions of cytokines and chemokines in the inflammatory exudate at 4 h and 10 h are shown. Data expressed as individual values with mean6SD. n55/
group. *P < 0.05, **< 0.01.
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Figure 5 Anabasum differentially regulates specialized pro-resolving mediators (SPMs) and prostanoids. Healthy male volunteers were randomized to
receive by oral route either placebo, 5 mg anabasum, 20 mg anabasum, twice daily, or 15 mg prednisolone once daily for 4 days. On the fourth day, acute
inflammation was triggered by intradermal injection of 1.5 3 107 UV-killed E. coli (UVkEc) suspended in 100 lL of saline in both forearms. Inflammatory
exudate at the injection site was acquired from the suction blister raised after 4 h (onset phase) on one forearm and after 10 h (resolution phase) on the
contralateral forearm. Lipid mediators in the inflammatory exudate were analyzed by liquid chromatography mass spectrophotometry (LC-MS) in Prof. Ser-
han’s laboratory (Harvard University). The concentrations of SPMs and prostanoids in the inflammatory exudate at 4 h and 10 h are shown. Data
expressed as individual values with mean6SD. n55/group. *P < 0.05, **< 0.01, ***< 0.001, ****< 0.0001.
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Anabasum increased vascular hyperemia around the site of
inflammation
Using laser Doppler, we were able to determine changes in vascu-
lar hyperemia surrounding the site of inﬂammation. As shown
previously, this was found to peak at 24 h and to decline thereaf-
ter up to 72 h.13 Of interest, this reduction in microvascular
hyperemia always occurs once neutrophils have been cleared and
macrophage populations have fully populated the inﬂamed site.13
Anabasum at 5mg b.i.d. and 20mg b.i.d. caused a dose-
dependent increase in microvascular hyperemia that nonetheless
resolved at the same rate as in placebo controls (Figure 6a)
with representative laser Doppler and skin images shown in
Figure 6b. To ensure that this increase in redness at the site of
inﬂammation following 20mg b.i.d. anabasum was not indicative
of enhanced localized or rebound inﬂammation, we elicited suction
blister over these site in an additional group of volunteers at 24 h
and 48 h and found that there were equivalent numbers of neutro-
phil in this group compared to placebo controls (Figure 6c).
Figure 6 Anabasum alters vascular hyperemia at the site of UVkEc triggered self-resolving dermal inflammation. Healthy male volunteers were random-
ized to receive by oral route either placebo, 5 mg anabasum, 20 mg anabasum, twice daily, or 15 mg prednisolone once daily for 4 days. On the fourth
day, acute inflammation was triggered by intradermal injection of 1.5 3 107 UV-killed E. coli (UVkEc) suspended in 100 lL of saline in both forearms. Vas-
cular hyperemia at the injection site was assessed at specified intervals by a laser Doppler imager. The comparison of vascular hyperemia (mean6SD)
between the four treatment groups (a), the representative Doppler flux images at 24 h and 48 h in the four treatment groups (b) and the neutrophil count
at 24 h and 48 h in the placebo and 20 mg anabasum (c) are shown. Data expressed as individual values with mean6SD. n55/group.
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Indeed, clinical examination of the inﬂamed site revealed that the
increased vascular hyperemia trigger by anabasum was not edema-
tous or painful and was therefore concluded not to be inﬂamma-
tory in nature.
Anabasum enhances bacterial clearance
One of the key determinants of inﬂammatory resolution is anti-
gen clearance.4 Indeed, both 5mg b.i.d. and 20mg b.i.d. anaba-
sum caused a profound reduction in levels of endotoxin within
the elicited blister ﬂuid, whereas prednisolone had no effect; in
fact, there appeared to be an increase in endotoxin levels by pred-
nisolone compared to placebo controls at 10 h (Figure 7a). To
understand how anabasum caused this reduction in endotoxin
levels, we questioned whether there was a correlation between
endogenous regulators of bacterial phagocytosis and levels of
endotoxin. For instance, PGE2 is known to impair bacterial
phagocytosis, while SPM has been shown to enhance bacterial
clearance.22–24 Therefore, we carried out post-hoc correlation
analysis between levels of blister ﬂuid endotoxin levels vs. blister
ﬂuid prostanoids and SPM levels (Figure S4). It transpired that
there is a direct correlation between PGE2/endotoxin
(P5 0.0167 and r5 1.0) as well as TxB2/endotoxin (P5 0.0167
and r5 1.0). No signiﬁcant correlation was obtained with
SPMs/endotoxin (Figure S4). To determine whether anabasum’s
inhibition of PGE2 and TxB2 at 4 h caused a reduction in blister
endotoxin, we incubated whole blood with anabasum for 4 h fol-
lowed by LPS for 15min, after which time samples were spiked
with FITC-labeled E. coli bioparticles. However, anabasum did
not directly enhance E. coli bioparticles uptake (Figure 7b).
Moreover, a combination of RvD3, LXB4, RvD1, and LXA4
were also without effect in this phagocytosis assay (Figure 7c).
We repeated these experiments, but stimulated with LPS for 4 h
to represent conditions within the 4-h blister site. Here, anaba-
sum caused an increased uptake of E. coli bioparticles at 0.1 lM,
which is equivalent to plasma levels of anabasum found in blood
after dosing with 5mg b.i.d. Importantly, this increased uptake
was reversed by PGE2 and TXB2 at levels found in the blister
ﬂuid at 4 h post-anabasum (Figure 7d). These results support the
hypothesis that reduced endotoxin levels brought about by anaba-
sum at 4 h resulted from the inhibition of antiphagocytic prosta-
noids. An interesting observation was an inverse correlation
between local blood ﬂow as measured by laser Doppler vs. and
blister endotoxin levels, where greater local blood ﬂow was associ-
ated with lower endotoxin levels, (P5 0.0167 and r5 1) (Figure
S4).
DISCUSSION
In this study, we found that anabasum, a selective CB2 receptor
agonist with minimal cannabimetic CNS activity, exerts potent
anti-inﬂammatory, anti-infective, as well as a pro-resolution effect
in a model of self-resolving acute inﬂammation in healthy human
volunteers. The anti-inﬂammatory properties of anabasum arose
from the inhibition of the neutrophil chemoattractant LTB4,
thereby reducing neutrophil inﬁltration and hence the potential
for further neutrophil-mediated tissue damage and propagation
of inﬂammation. Moreover, in line with the classic deﬁnition of
resolution, anabasum hastened antigen clearance, which alongside
increased biosynthesis of SPMs at the 20mg b.i.d. dose collec-
tively resulted in effects that were superior to that of predniso-
lone. We propose, therefore, that anabasum is the ﬁrst of a new
generation of anti-inﬂammatory/pro-resolving drug that acts on
diverse aspects of the immune response bringing back into
homeostatic check multiple proinﬂammatory pathways that are
activated by infection or injury. These unique pharmacological
properties of anabasum appear to exert a more favorable effect on
human pathophysiology compared to the properties of steroids,
which as a consequence of their broad actions carry with them a
burden of immunosuppressive side effects not seen with
anabasum.
Treating neutrophils with anabasum for 4 h followed by LPS
for 15min did not alter their ability to engulf bacteria compared
to untreated controls. If we extended the LPS-stimulation time
to 4 h then anabasum signiﬁcantly enhanced the ability to neu-
trophils to phagocytose labeled E. coli bioparticles. These experi-
mental conditions, which are akin to the 4 h blister setting and
where anabasum signiﬁcantly inhibits endotoxin levels, suggest
that anabasum either triggered the release of prophagocytic fac-
tor/s or inhibited the synthesis of factor/s that impair bacterial
uptake. While SPMs have been shown to enhance bacterial kill-
ing in various settings,25 anabasum did not alter levels of these
lipid mediators at 4 h. However, it did dose-dependently and sig-
niﬁcantly inhibit synthesis of both PGE2 and TxB2. Moreover,
adding these prostanoids back to the ex vivo phagocytosis assays
reversed anabasum’s uptake of labeled bacteria. PGE2 has been
shown to inhibit NADPH oxidase-mediated bacterial killing via
upregulation of cAMP26 and also inhibit FcgR-mediated phago-
cytosis22,27; indeed, we have shown that its elevation in cirrhosis
patients underpins their susceptibility to infection that is typical
of these individuals.28 Moreover, a post-hoc analysis revealed a sig-
niﬁcant correlation between levels of blister ﬂuid endotoxin at
4 h and PGE2 as well as TXB2 such that when levels of these
prostanoids were inhibited, so also were levels of endotoxin.
Thus, inhibiting prostanoid biosynthesis could explain how ana-
basum reduced endotoxin levels.
There was also a strong correlation between the inhibition of
TxB2 by anabasum (5mg b.i.d.) and endotoxin levels at 4 h in eli-
cited blister ﬂuid. While there is little evidence that thromboxane
can directly affect neutrophil and/or macrophage bacterial phago-
cytosis, we did ﬁnd that TxB2 blocked anabasum-mediated
uptake of E. coli bioparticles by neutrophils. However, there is
also compelling evidence that TxA2-mediated vasoconstriction
may decrease the numbers of bacteria leaving the site of infec-
tion,29 supporting the hypothesis that this may be an important
mechanism by which TxA2 may regulate immune responses to
infection in vivo. Indeed, we found that levels of TxB2 after ana-
basum at 4 h (5mg b.i.d.) correlated inversely (P5 0.0167 and
r5 1) with local vascular blood ﬂow as determined by laser
Doppler. Thus, the mechanism by which anabasum lowered
endotoxin levels could be due to increased phagocytosis and/or
reverse migration to systemic circulation; however, the latter
seems unlikely, as there was no spike in systemic CRP levels.
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Figure 7 Anabasum actively clears UVkEc endotoxin from the site of inflammation. Healthy male volunteers were randomized to receive by oral route either pla-
cebo, 5mg anabasum, 20mg anabasum, twice daily, or 15 mg prednisolone once daily for 4 days. On the fourth day, acute inflammation was triggered by intra-
dermal injection of 1.53 107 UV-killed E. coli (UVkEc) suspended in 100 lL of saline in both forearms. Inflammatory exudate at the injection site was acquired
into a suction blister raised after 4h (onset phase) on one forearm and after 10h (resolution phase) on the contralateral forearm. Endotoxin as a surrogate for
inflammatory stimulus (UVkEc) was measured using the kinetic turbidimetric limulus ameobocyte lysate test. The relative concentration of endotoxin in the inflam-
matory exudate at 4h and 10h is shown (a). Whole blood from healthy volunteers was incubated with anabasum for 4h before adding 0.1 lg/mL LPS for 15 min,
after which time red blood cells were lysed and remaining leukocytes incubated with AF488-labeled E. coli bioparticles and analyzed by flow cytometry to determine
neutrophil phagocytosis (b). For comparison, lysed whole blood was stimulated with varying concentrations of SPMs (RvD3, LXB4, RvD1, and LXA4) for 15 min
before incubating with AF488 E. coli bioparticles for 15 min and analyzed by flow cytometry (c). Experiments in panel b were repeated but incubated with 0.1 lg/
mL LPS for 4h with and without either 10 ng/mL dmPGE2 or a TxA2 receptor agonist (CTA2) (d); the idea was to replicate, as much as possible, the events occur-
ring at the site of inflammation at 4 h where anabasum inhibited prophagocytic prostanoid biosynthesis. Data expressed as individual values with mean6SD.
n55/group. **P< 0.01.
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While there are many effective anti-inﬂammatory treatment
regimens on the market (nonsteroidal anti-inﬂammatory drugs
(NSAIDs), anticytokine therapies, steroids, etc.), switching off
the underlying disease process is much more challenging. In terms
of diseases driven by ongoing inﬂammation, the rationale is there-
fore to activate pro-resolution pathways that might be pathologi-
cally silenced and/or activate functional pro-resolution pathways
to ameliorate persistent inﬂammation.4 Indeed, it may transpire
that combining pro-resolution with anti-inﬂammatory technol-
ogy may represent a superior strategy to existing approaches.
Along these lines, it was originally feared that hastening resolu-
tion might lead to incomplete clearance of the original trigger,
especially in the context of infections. Specialized pro-resolution
mediators, for instance, have to date been shown not just to aug-
ment resolution processes such as nonphlogistic monocyte
recruitment and efferocytosis of neutrophils, but also antimicro-
bial properties.30 Indeed, while NSAIDs are clearly anti-
inﬂammatory, they also augment host defense. Therefore, it must
be emphasized that dampening inﬂammation is not necessarily
associated with compromised host defense.
While anabasum was effective at dampening neutrophil traf-
ﬁcking and hastening antigen clearance in a self-resolving model
of inﬂammation in healthy volunteers, its ability to exert similar
actions on chronic inﬂammatory disease has been documented as
well. In a rat adjuvant arthritis model, anabasum reduced inﬂam-
mation, weight loss, pannus formation in the joints, and joint tis-
sue injury over the entire 4-week period of the study.31,32
Likewise, in bleomycin-induced lung and dermal inﬂammation
and ﬁbrosis models, anabasum, administered therapeutically after
the start of bleomycin, inhibited organ ﬁbrosis, collagen deposi-
tion, and myoﬁbroblast differentiation.33,34 In clinical studies
anabasum treatment over a 12-week period has been shown to
reduce skin thickening in systemic sclerosis patients, and the rate
and number of pulmonary exacerbations and inﬂammatory bio-
markers in cystic ﬁbrosis patients.35,36
One interesting observation made during this study was that
anabasum caused a dose-dependent increase in local microvascu-
lar hyperemia around the injection site. While this suggested
increased “inﬂammatory ﬂare,” upon clinical examination the site
was neither edematous nor painful. Moreover, we found no
increase in neutrophils or macrophages in the affected tissue. In
order to understand the mechanism underlying this observation,
we measured levels of nitrite/nitrate in the blister ﬂuid and found
no evidence of increased NO biosynthesis (Figure S5). However,
anabasum dose-dependently inhibited TxB2, but was without
effect on prostacyclin, measured as 6-keto PGF1a (Figure S6).
This inhibition of a potent vasoconstrictor while keeping levels
of the vasodilator prostacyclin unaffected could result in a net
increase in local microvascular hyperemia. Indeed, these data are
very reminiscent of the beneﬁcial effects of low-dose aspirin on
pathophysiology, namely, the inhibition of vasoconstrictive
thromboxane while maintaining prostacyclin levels due to its
preference for acetylating platelets in the portal circulation.
While both doses of anabasum inhibited inﬂammation, the
mechanisms by which it exerted this potent effect may be dose-
speciﬁc. For instance, at 20mg b.i.d. anabasum increased levels of
LXA4, LXB4, RvD1, and RvD3, which is of interest because each
one of these mediators carries potent pro-resolving actions. For
instance, LXA4 and RvD1 reduce human neutrophilic chemo-
taxis and inﬁltration,37 while RvD3 increases efferocytosis and
phagocytosis, while, alongside aspirin-triggered RvD3, are potent
immunoresolvents.38,39 In contrast, 5mg b.i.d. anabasum had no
effect on these SPMs. PGE2 and TxB2 inhibition occurred with
both 5mg b.i.d. and 20mg b.i.d. doses. These ﬁndings suggest
lower concentrations of anabasum or lower levels of CB2 recep-
tor occupancy have metabolic effects on the arachidonic acid
pathway, whereas higher concentrations are required to trigger
SPM synthesis pathways. Thus, 20mg b.i.d. may activate both
effects of anabasum, whereas 5mg b.i.d. only activates metabolic
effects on the arachidonic acid pathway, at least in the setting of
exposure limited to 4 days. These data suggest that 20mg b.i.d.
may be a more effective therapeutic dose of anabasum for treating
chronic inﬂammatory diseases because it engages resolution path-
ways, with the acknowledgment that a longer duration of expo-
sure to lower doses might also lead to activation of resolution
pathways.
In summary, we used UV-killed E. coli-driven acute dermal
inﬂammation to report the potent anti-inﬂammatory properties
of the CB2 receptor agonist, anabasum. Speciﬁcally, anabasum
was as efﬁcacious as prednisolone in inhibiting neutrophil inﬁl-
tration and also accelerated the clearance of the injected bacteria,
a key determinant for the resolution of inﬂammation. It tran-
spires that its mode of action is, at least in part, through inhibi-
tion of chemoattractant LTB4, as well as through inhibition of
antiphagocytic prostanoids, while maintaining levels of the vaso-
dilator prostacyclin. Anabasum also triggered specialized pro-
resolving lipid mediators including lipoxins and resolvins. There-
fore, anabasum exerts its effects on multiple aspects of the inﬂam-
matory and resolution cascade, resulting in both anti-
inﬂammatory and pro-resolving properties in a manner that does
not appear to compromise host defense or vascular homeostasis.
METHODS
Ethics statement
Study approval was obtained from UCL Institutional Ethics Committee
(Project ID: 5051/002). All volunteers provided written informed
consent.
Study design and volunteer recruitment
Healthy, young (18–45 years) male volunteers were recruited for this
study. An open-label, randomized, parallel group, placebo-controlled
study was conducted and the volunteers were randomized to one of four
study groups: Group A: placebo, twice daily for 4 days, oral. Group B:
5mg anabasum, twice daily for 4 days, oral. Group C: 20mg anabasum,
twice daily for 4 days, oral, Group D: 15mg prednisolone, single morn-
ing dose for 4 days, oral (Figure 1). The study exclusion criteria are
detailed in the Supplementary Methods.
Human model of self-resolving acute dermal inflammation
The model was performed as described previously.13 Brieﬂy, acute
inﬂammation was triggered by intradermal injection of 1.5 3 107
UVkEc bacteria (Strain: NCTC 10418, Public Health England, UK)
suspended in 100 lL of saline in both the forearm of healthy volunteers.
Using negative pressure, a skin blister was created over the inﬂamed site
to acquire inﬂammatory exudate at 4 h (onset phase) on one forearm
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and at 10 h (resolution phase) on the contralateral forearm after the
UVkEc injection. Cells in the inﬂammatory exudate were processed
immediately for ﬂow cytometry (described in the Supplementary Meth-
ods) and the cell free exudate was frozen into aliquots at –808C and was
analyzed later for soluble mediators including cytokines and lipid media-
tors (described in the Supplementary Methods). Cell count in inﬂam-
matory exudate was obtained using an automatic cell counter (ADAM
MC 2000, NanoEntek, South Korea). To assess local vascular hyperemia,
the forearm was scanned by a laser Doppler imager (moorLDI, UK) at
speciﬁc intervals after UVkEc injection.
Endotoxin measurement
Endotoxin in the blister exudate was measured using the Pyrogent-5000
endotoxin measurement kit (Lonza, Basel, Switzerland) as per the manu-
facturer’s instructions. For use with this kit, the cell-free blister exudate
was ﬁrst treated, as recommended previously for human biological matri-
ces,40 by diluting 1:20 in 0.1% tween 80 buffer (Sigma, St. Louis, MO)
to a ﬁnal volume of 100 lL, followed by heating at 708C for 15min.
Phagocytosis assay
One ml of ethylenediamine-tetraacetic acid (EDTA) anticoagulated
whole blood was mixed with 4mL of RPMI. The mixture was then incu-
bated with 0.1, 1, and 10 lM anabasum for 4 h at 378C, and then
0.1 lg/mL of LPS was added for an additional 4 h with or without
10 ng/mL dmPGE2 and CTA2. One 3 10
7 AF488 labeled E. coli (K-12
strain) BioParticles were opsonized with autologous serum, and incu-
bated with 500,000 lysed whole blood cells for 15min at 378C before
stopping with 1% paraformaldehyde (PFA). Samples were quenched
with 0.4mg/mL Trypan blue before reading on an LSR II Fortessa ﬂow
cytometer. For SPM experiments, lysed whole blood was incubated for
15min at 378C with SPM (RvD3, LXB4, RvD1, and LXA4) before incu-
bating with bioparticles as above.
Statistical analysis
GraphPad Prism software (v. 7, San Diego, CA) was used for statistical
analysis. Data are presented as individual values with the mean6
standard deviation (SD) on a linear scale. For normally distributed data,
differences between groups were tested for statistical signiﬁcance by ordi-
nary one-way analysis of variance (ANOVA) followed by Bonferroni’s
test to correct for multiple comparisons. For non-normal distributed
data, differences were detected by the Kruskal–Wallis test (for unpaired
data) followed by Dunn’s test to correct for multiple comparisons. Spear-
man correlation was performed to test correlation between variables.
P < 0.05 was taken as signiﬁcant.
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